Patents by Inventor Neeraj Agarwal

Neeraj Agarwal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7572781
    Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: August 11, 2009
    Assignees: University of Florida, University of North Texas Health Science Center
    Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
  • Publication number: 20070155711
    Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcomeal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocomeal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
    Type: Application
    Filed: February 15, 2007
    Publication date: July 5, 2007
    Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
  • Patent number: 7186707
    Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: March 6, 2007
    Assignees: University of Florida, University of North Texas Health Science Center
    Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
  • Publication number: 20040171596
    Abstract: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
    Type: Application
    Filed: December 9, 2003
    Publication date: September 2, 2004
    Inventors: Laszlo Prokai, Katalin Prokai, James Simpkins, Neeraj Agarwal
  • Patent number: 6714976
    Abstract: Systems and methods for automated monitoring and management of distributed applications, client/server databases, networks and systems across heterogeneous environments. Distributed, automated intelligent monitoring agents use embedded sensing technology which is knowledgeable of application protocols, to monitor continuously the network environment in real time. To this end, the monitoring agent can be located on each client and server in the network. The monitoring agent can couple to the communications stack for monitoring the data that is being passed between the client and the network, of a server in the network. The data can be collected and employed for trouble shooting trend analysis, resource planning, security auditing, and accounting as well as other applications. Also included is a controller for remotely coordinating the data gathering process from the various clients and servers.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: March 30, 2004
    Assignee: Concord Communications, Inc.
    Inventors: James Wilson, Neeraj Agarwal, Gary Fernandez, Murtaza Doctor, Ken Kane, Albert Briner, Sehkar Muddana, Pieter deGroot, John Lyon-Smith, Scott Mendel
  • Patent number: 5958010
    Abstract: Systems and methods for automated monitoring and management of distributed applications, client/server databases, networks and systems across heterogeneous environment The invention employs distributed, automated intelligent monitoring agents with embedded sensing technology which is knowledgeable of application protocols, to monitor continuously the network environment in real time. To this end, the monitoring agent can be located on each client and server in the network. The monitoring agent can couple to the communications stack for monitoring the data that is being passed between the client and the network, of a server in the network. The data can be collected and employed for trouble shooting trend analysis, resource planning, security auditing, accounting and chargeback, as well as other applications.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: September 28, 1999
    Assignee: FirstSense Software, Inc.
    Inventors: Neeraj Agarwal, Pierre Perret, Michael G. McMenemy